Gapping down
In reaction to earnings/guidance:
- TTGT -29.8%, VWE -25.1% (issues downside Q2 rev guidance; CEO to transition to Exec Chairman; announces reorganization and simplification of ops), APPS -18.1%, AFRM -18% (also announces 19% workforce reduction), MAT -10.5%, STE -9.2%, TTMI -8.5% (also to close three manufacturing facilities), BAX -8.2%, RPD -8%, FROG -7.1%, CS -7%, AZTA -6.2%, TPX -5.8%, IFF -5.7%, IPG -4.6%, MAS -3.9%, LNC -3.8%, EFX -3.5%, TRI -2.9%, BTI -2.7%, THC -2.5%, THC -2.5%, PAA -2.4%, NVST -2.3%, VKTX -2.2%, HI -2%, SON -2%, REXR -1.7%, ASGN -1.1%, EQH -1.1%, PTEN -1%, SEE -1%
Other news:
- PRPL -16.4% (prices offering of 13.4 mln shares of common stock at $4.50 per share)
- GMED -11.6% (NuVasive and Globus Medical (GMED) confirm the two parties will combine in all-stock merger)
- APPH -11.5% (commences $40 mln stock offering)
- GLPG -8.3% (topline results from Phase 3 DIVERSITY trial of filgotinib)
- NSSC -4.8% (prices secondary offering 2.1 mln shares of common stock at $31.50 per share)
- RBT -3.5% (stock offering)
Analyst comments:
- UNVR -1.5% (downgraded to Neutral from Buy at UBS)
- ACCD -0.9% (downgraded to Hold from Buy at Jefferies)